Leading GMP cell CDMO I Peace, Inc. ( specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has established low immunoreaction risk GMP ...

With the offering of these off-the-shelf, low immunoreaction risk iPSCs, I Peace's iPSC offerings have been enriched to serve a wider variety of cell therapy developers and pharmaceutical companies.

To realize iPS cell therapy in a clinical setting, we have to overcome their tumorigenicity. An iPS cell line without exogenous gene integration should be used. iPS cell therapy can be applied ...

Personalized organoids — ‘mini-organs’ — may accelerate treatment for patients with rare genetic disorders. Courtesy of Europeana via Unsplash Across the globe, countless babies ...

4 Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany Objectives CD19-targeting chimeric ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.

becoming the focus of extensive works worldwide to develop cell-based approaches for a variety of diseases. Initial evidence for the effectiveness of MSCs therapy comes from the restoration of dynamic ...

Background: The use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R ...

In his book “Why We Die: The Science of Aging and the Quest for Immortality,” Venki Ramakrishnan, a winner of the 2009 Nobel ...